Rajesh Narwal
About Rajesh Narwal
Rajesh Narwal is the Senior Director and Early Development Program Lead at Bristol Myers Squibb, with extensive experience in clinical pharmacology and pharmacometrics from his previous roles at Medimmune/AstraZeneca and other organizations.
Company
Rajesh Narwal is currently employed at Bristol Myers Squibb, where he holds the position of Senior Director, Early Development Program Lead (EDPL).
Title
Rajesh Narwal serves as the Senior Director, Early Development Program Lead (EDPL) at Bristol Myers Squibb.
Education and Expertise
Rajesh Narwal completed his Bachelor's degree in Pharmacy from Guru Jambheshwar University from 1996 to 2000. He furthered his education at the University of Rhode Island, where he achieved both an MS and PhD in Pharmacokinetics/Pharmacometrics, studying from 2002 to 2005 for his MS and from 2005 to 2008 for his PhD. His education and expertise lie in Pharmacokinetics, Pharmacometrics, and Clinical Pharmacology.
Professional Background
Rajesh Narwal's professional background includes significant roles at renowned pharmaceutical organizations. He worked at Medimmune/AstraZeneca from 2008 to 2020, advancing from Clinical Pharmacokineticist to Group Director, Clinical Pharmacology and Pharmacometrics in Gaithersburg, MD. Prior to that, he served as a Research Assistant at FDA/CDER in Silver Spring, MD, and held a Summer Intern position at Vertex Pharmaceuticals in Cambridge, MA. Rajesh also worked as a Research Assistant/Manufacturing Chemist at Jagsonpal Pharmaceutical Ltd in Faridabad Area, India, from 2000 to 2002.
Achievements
Rajesh Narwal has led the development of over 15 programs ranging from early to late stage across multiple therapeutic areas. His roles included providing oversight and review of IND and BLA submissions, leading cross-functional teams for immuno-oncology clinical development, and guiding model-informed drug development (MIDD). His broad experience encompasses leading data analytics teams responsible for translational PK/PD, exposure-efficacy/safety, dose selection, biomarker, and disease modeling. He is also recognized as a key oncology product/functional leader for strategic, scientific, regulatory, and governance interactions.